Blood neurofilament light chain measurements in adults with CNS histiocytic neoplasms - Takeaways - MDSpire

Blood neurofilament light chain measurements in adults with CNS histiocytic neoplasms

  • By

  • Samantha A. Banks

  • Paul Decker

  • Eoin P. Flanagan

  • Anastasia Zekeridou

  • Ronald S. Go

  • Jithma P. Abeykoon

  • Gaurav Goyal

  • Jason R. Young

  • Matthew J. Koster

  • Robert Vassallo

  • Jay H. Ryu

  • Caroline J. Davidge-Pitts

  • Aishwarya Ravindran

  • Julio C. Sartori Valinotti

  • N. Nora Bennani

  • Mithun V. Shah

  • Karen L. Rech

  • Corrie R. Bach

  • Jeanette E. Eckel-Passow

  • W. Oliver Tobin

  • September 5, 2024

  • 0 min

Share

  • 1

    Histiocytic neoplasms are rare hematologic disorders that can significantly impact the central nervous system (CNS), leading to increased morbidity and mortality.

  • 2

    Neurofilament light chain (NfL) is a biomarker for axonal degeneration, showing potential for monitoring CNS disease activity in patients with histiocytic neoplasms.

  • 3

    Elevated NfL levels were significantly associated with CNS involvement and active CNS disease in patients with histiocytic neoplasms.

  • 4

    The study included 83 patients with various types of histiocytic neoplasms, with 51% diagnosed with Erdheim-Chester disease (ECD) and 28% with Langerhans cell histiocytosis (LCH).

  • 5

    BRAF mutations were present in 43% of patients tested, with a higher prevalence in those exhibiting CNS involvement compared to those without.

Original Source(s)

Related Content